Proposed consolidation of share capital (2824B)
April 13 2012 - 4:03AM
UK Regulatory
TIDMNGG
RNS Number : 2824B
NextGen Group PLC
13 April 2012
13 April 2012
NextGen Group Plc
Proposed consolidation of share capital
Further to the announcement on 2 April 2012 of a Notice of AGM,
the Company wishes to draw shareholders' attention to the proposed
resolution to consolidate the Company's ordinary shares (Resolution
6) and the explanation for this proposal which is also set out in
the Notice of AGM. Should the resolution be passed, then every 500
ordinary shares of 0.1p will be consolidated into one new ordinary
share of 50p. Further details are set out in the Notice of AGM
which is available on the Company's website:
www.nextgensciences.com.
ENDS
For further details please contact:
Klaus Rosenau
Chairman
NextGen Group
Tel: +49 (0)160 5516756
Barry McAleer PhD
CEO
NextGen Sciences Inc
Tel: +44 (0)7825 413 110
Nicola Marrin/Jonathan Wright (Nominated Adviser)
David Banks (Broker)
Tel: + 44 (0)20 7107 8000
Seymour Pierce Limited
Notes to Editors:
NextGen Group Plc (AIM: NGG) is a provider of biomarker services
for pharmaceutical and biotech companies globally through its
USA-based subsidiary, NextGen Sciences Inc and a developer of
diagnostic markers and assays through its second US-based
subsidiary, NextGen Sciences Dx. Using advanced techniques, such as
Multiple Reaction Monitoring (MRM) mass spectrometry analysis, the
Company is developing a portfolio of robust assays for testing
clinical samples for drug safety and efficacy, and the development
of personalized treatment for patients.
NextGen Sciences Inc is a wholly owned, operational subsidiary
of NextGen Group Plc and is headquartered in Ann Arbor, Michigan,
USA. NextGen Sciences' range of services, which include biomarker
discovery, assay development, validation and testing are employed
by its customers as a key part of the biomarker-based drug and
diagnostic development process.
NextGen Sciences Dx is a wholly owned, operational subsidiary of
NextGen Group Plc and is headquartered in Boston, Massachusetts,
USA. NextGen Sciences Dx utilises the expertise of NextGen Sciences
Inc to discover biomarkers and develop assays for point-of-care
diagnostics, to assist in patient treatment, for selection of
patients for clinical trials and to aid decision-making on efficacy
determination for therapeutic development.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGRGDSIUBBGDX
Nextgen (LSE:NGG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nextgen (LSE:NGG)
Historical Stock Chart
From Jul 2023 to Jul 2024